Immortalize Your Antibody
At R&D Systems, we have optimized a platform for custom recombinant antibody development. Utilize our expertise to quickly convert your existing clone to a recombinant antibody or to modify or engineer your critical antibody to meet your needs. Using our proprietary expression systems and modification library we increase expression and yield compared to a hybridoma, preventing lengthy lot bridging studies and allowing you to get the data needed to move your project forward.
Common Hybridoma Clone Conversion Platforms
Recombinant Antibody Conversion
For applications requiring large amounts of custom recombinant antibodies and consistent antibody supply, R&D Systems offers recombinant antibody conversion services to produce a dependable supply of custom engineered monoclonal antibody. R&D Systems proprietary processes guarantee the gram quantity yields required for the development of diagnostic and therapeutic reagents. Our custom recombinant antibody conversion process includes:
- Clone out hybridoma sequence
- Transfect with our optimized vector into our high yield cell line
- Small scale pilot lot production
- Large scale recombinant antibody production
- QC Testing
Recombinant Antibody Engineering
Harnessing recombinant technology, we can further engineer antibody fragments or edit your existing sequence to meet your specific research goals. Producing fragments recombinantly has many benefits including less variability than enzymatic options, higher yields, and a defined antibody product. We can further leverage this technology to produce affinity reagents such as scFvs, bi-specifics, or full-length antibodies with a defined Fc region devoid of glycosylation sites. Our custom recombinant antibody engineering process includes:
- Clone out hybridoma sequence
- Small scale antibody screening
- Construct design
- Small scale fragment production and testing
- Large scale recombinant antibody production
- QC Testing
Chimeric Antigen Receptor (CAR) Design
R&D Systems has an existing library of chimeric antigen receptor validated single chains, and a validation program for faster development of CARs for your target. This platform and our proprietary hinge designs, allow us to quickly build a CAR panel for testing in your system. Our CAR designprocess includes:
- Clone out hybridoma sequence
- Small scale antibody screening
- Construct design
- Small scale fragment production and testing
- Large scale recombinant antibody production
- QC Testing
R&D Systems Advantage
Antibodies play a critical role in diagnostics and therapeutics. Consistency of antibody quality attributes is key in these applications. Recombinant conversion of existing hybridomas offers many advantages, among these are recombinant antibody consistency, long term supply, high yields, and the ability to engineer antibody fragments or existing sequence. As the industry moves towards dependence on recombinant antibody technologies, R&D Systems is on the leading edge of these efforts and is steadily advancing the field of antibody engineering.
Solutions to improve screening method
Discover how our custom recombinant antibody services empowered a client’s drug discovery pipeline by providing tools which improve their screening methods.
Case Study: Existing Antibodies Reinvented into Novel Bispecific Affinity Reagents
THE PROBLEM:
A pharmaceutical company had been a long-time purchaser of antibodies to important oncology markers. The company was using these antibodies to study cell-to-cell interactions in order to find potential therapeutic targets. With the recent advancements in immune cell therapy, the company wanted to reinvent their methodology, increasing their chance of success. They needed the specificity of the old antibodies, but with targeting ability of a bispecific affinity reagent.
Testimonials
Conversion of our traditional monoclonal to recombinant antibody offered immortal supply of a very high quality product. We also liked the feature of the recombinant technology to be able to exchange the constant chain between different species and the ability to express the antibody as Fab fragments.
Principal Scientist, Biotech Company